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Clinical Streptococcus pneumoniae isolates
induce differing CXCL8 responses from
human nasopharyngeal epithelial cells
which are reduced by liposomes
Denja Baumgartner1, Suzanne Aebi1, Denis Grandgirard1, Stephen L. Leib1, Annette Draeger2,
Eduard Babiychuk2 and Lucy J. Hathaway1*
Abstract
Background: Streptococcus pneumoniae causes several human diseases, including pneumonia and meningitis, in
which pathology is associated with an excessive inflammatory response. A major inducer of this response is the
cholesterol dependent pneumococcal toxin, pneumolysin. Here, we measured the amount of inflammatory
cytokine CXCL8 (interleukin (IL)-8) by ELISA released by human nasopharyngeal epithelial (Detroit 562) cells as
inflammatory response to a 24 h exposure to different pneumococcal strains.
Results: We found pneumolysin to be the major factor influencing the CXCL8 response. Cholesterol and
sphingomyelin-containing liposomes designed to sequester pneumolysin were highly effective at reducing CXCL8
levels from epithelial cells exposed to different clinical pneumococcal isolates. These liposomes also reduced CXCL8
response from epithelial cells exposed to pneumolysin knock-out mutants of S. pneumoniae indicating that they also
reduce the CXCL8-inducing effect of an unidentified pneumococcal virulence factor, in addition to pneumolysin.
Conclusion: The results indicate the potential of liposomes in attenuating excessive inflammation as a future
adjunctive treatment of pneumococcal diseases.
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Background
Streptococcus pneumoniae is a major human pathogen
responsible for diseases including pneumonia and men-
ingitis which are characterized by significant inflamma-
tory responses [1]. Such responses are associated with
the release of cytokines including CXCL8, also known as
interleukin (IL)-8 as well as IL-6, IL-1β, granulocyte-
macrophage colony stimulating factor (GM_CSF), trans-
forming growth factor (TGF) α and β [2]. Triggering of
an inflammatory response may be due to interaction be-
tween host cells and several different bacterial factors.
Respiratory epithelial cells express pattern-recognition
receptors (PRRs) such as Toll-like receptors (TLRs) 2–6
with TLR2 recognizing bacterial factors such as pep-
tidoglycan and lipoteichoic acid [3]. Epithelial cells
expressing TLRs may release CXCL8 during respira-
tory infection which has chemotactic activity for neu-
trophils and monocytes [4]. Innate immunity is also
comprised of antimicrobial effectors including anti-
microbial peptides which have been shown to be ef-
fective against S. pneumoniae [5].
Excessive inflammation can have a deleterious effect on
the host and therefore treatments are sought which can
moderate this response to the bacteria. A major trigger for
inflammatory cytokine release from the host is thought to
be the cholesterol-dependent toxin, pneumolysin. However,
natural variants of pneumolysin exist with different haemo-
lytic activity, particularly a non-haemolytic pneumolysin
associated with serotype 1 strains of multi-locus sequence
type (MLST) ST306 [6, 7]. A liposomal formulation has
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been designed with the specific aim of sequestering
pore-forming toxins, including pneumolysin, thereby
preventing it from inserting into host cell membranes
and initiating the inflammatory response [8]. These li-
posomes have so far been tested on a limited number
of pneumococcal strains [8, 9].
As well as the virulence factor pneumolysin, most
pneumococci express one of more than 90 different poly-
saccharide capsules [10]. The presence or absence of poly-
saccharide capsule can affect CXCL8 release by human
respiratory epithelial cells in vitro [11] but whether the
capsule serotype plays a role in CXCL8 induction is un-
known. Here we have tested whether clinical isolates of
different serotypes induced different levels of CXCL8 re-
lease from respiratory epithelial cells and whether this is
linked to capsule type using mutants with the same gen-
etic background expressing capsules of different serotypes.
To date, studies on the effectiveness of liposomes have
been confined to a limited number of pneumococcal
strains. Here we tested the effectiveness of liposomes
against a panel of clinical isolates including serotype 1
strains of different haemolytic activity. Pneumolysin mu-
tants were also tested to determine whether these lipo-
somes had an effect on any other CXCL8-inducing
bacterial factor.
Methods
Bacterial strains
Fourteen wild type Streptococcus pneumoniae strains
with different serotypes and haemolytic activity were
used, including strain 202.67, a non-haemolytic serotype
1 strain of ST306. Also used were one non-encapsulated
mutant of strain 106.66 (named 106.66 Janus) and 8 cap-
sule switch mutants of strain 106.66, for example mutant
106.66cpsB201.73 refers to strain 106.66 (originally sero-
type 6B) which has had its capsule operon replaced by
that of strain B201.73 resulting in it becoming serotype
19 F [12].
Also, 3 mutants of the D39 strain in which the pneu-
molysin and/or capsule gene had been deleted were
used. The D39 strain lacking pneumolysin (D39Δply)
was a kind gift of Jeremy Brown, UCL, London. The bac-
teria are listed in Table 1 and mutant construction is de-
scribed in previous publications [11, 12].
Bacterial culture
Bacterial stocks were stored at −80 °C using Protect
bacterial preservers (Technical Service Consultants,
Heywood, U.K.). The bacteria were plated out on
Columbia sheep blood agar (CSBA) plates and incubated
overnight at 37 °C at 5 % CO2. Three to ten colonies
were used to inoculate 5 ml Brain Heart Infusion (BHI)
broth (Becton Dickinson and Company, le Pont de Claix,
France) for overnight culture in a waterbath at 37 °C.
1 ml of the overnight culture was added to 9 ml BHI
and incubated in a waterbath at 37 °C until reaching
mid-log phase, OD600nm = 0.4. The bacterial cells were
collected by centrifugation of 10 ml culture and were
washed with Minimum Essential Media (MEM, Gibco,
Life Technologies, Switzerland). The pellets were re-
suspended in 10 ml MEM.
Detroit cell culture
The human pharyngeal epithelial cell line Detroit 562
(ATCC CCL-138) was cultured submerged in complete
medium consisting of Minimum Essential Media (MEM)
with 10 % heat-inactivated fetal calf serum (FCS), 2 mM
of L-glutamine, 0.075 % sodium bicarbonate, 1x MEM
non-essential amino acid solution, 1 mM sodium pyru-
vate, 100 μg/ml streptomycin and 100 U/ml penicillin
Table 1 Wild type and mutant S. pneumoniae strains used
Strain Capsule serotype Description
B201.73 19F Wild types (clinical isolates) [12]
103.57 23F
B101.77 14
307.14 18C
109.74 9V
207.31 15
106.66 6B
208.41 7F
P21 3 Wild type [13]
106.66 Janus nonencapsulated Capsule operon replaced by a
Janus cassette [12]
106.66cps106.66 6B Capsule switch mutants [12]
106.66cpsB201.73 19F
106.66cps103.57 23F
106.66cpsB101.77 14
106.66cps307.14 18C
106.66cps109.74 9V
106.66cps207.31 15
106.66cps208.41 7F
B103.21 1 Wild type, non-haemolytic
(current study)
211.25 1 Wild type, poorly haemolytic
(current study)
207.06 1 Wild type, haemolytic (current study)
202.67 1 Wild type, non-haemolytic
(current study)
D39 2 Wild type [11]
D39Δply 2 Mutant lacking pneumolysin [11]
D39Δcps nonencapsulated Mutant lacking capsule [11]
D39ΔplyΔcps nonencapsulated Mutant lacking pneumolysin and
capsule [11]
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(all from Gibco, Life Technologies, Switzerland) at 37 °C
at 5 % CO2. Cells were harvested using 0.05 % Trypsin-
EDTA (Gibco, Switzerland) when the cells reached 70–
90 % confluence.
CXCL8 (IL-8) cytokine assay
3 × 105 Detroit cells in 1 ml MEM without antibiotics,
was added to each well of a 24-well plate (TPP tissue
culture plates, Sigma-Aldrich,). The plate was incubated
overnight at 37 °C at 5 % CO2 then integrity of the
monolayer checked by microscopy. The medium was as-
pirated and 0.5 ml MEM without FCS or antibiotics
added per well.
A suspension of bacteria of approximately 6 × 106 CFU/
ml was made (to give an estimated MOI of 10). Serial
dilutions of the suspension were plated out for accurate
quantification of CFU/ml, and therefore MOI.
Liposomes (CAL02) were provided by LASCCO (Geneva,
Switzerland) and have previously been shown to be neither
bactericidal nor toxic to epithelial cells [8] (Additional
file 1: Figure S2). The liposome concentrations utilized in
these experiments were chosen based preliminary experi-
ments using liposome concentration ranging from 50ug to
1 mg (data not shown). Therefore, 1 mg or 100 μg of lipo-
somes were added per well followed by 0.5 ml MEM con-
taining the bacteria (6 × 106 CFU/ml) in the subsequent
experiments The plate was centrifuged at 120 x g for
3 min at 25 °C and then incubated at 37 °C at 5 % CO2.
For experiments involving lysis of the P21 strain of
bacteria by antibiotic, 10 μl / well of a 10 mg/ml solution
of ceftriaxone (Rocephine®, Roche Pharma, Basel,
Switzerland) was added after 3 h of incubation. After incu-
bating for a total of 24 h at 37 °C at 5 % CO2 the super-
natant was collected in 1.5 ml tubes, spun down at 20 000
x g for 3 min at room temperature and the supernatant
stored at −80 °C. CXCL8 concentrations were measured
by ELISA (R&D systems ELISA kits, Abingdon, United
Kingdom). Experiments were performed in triplicate on
three different days. Mean CXCL8 concentration for
Detroit cells plus 1 mg liposomes, but no bacteria, for all
experiments involving liposomes was 412 pg/ml, indicat-
ing that the liposomes do not have a cytotoxic effect on
eukaryotic cells as reported previously [8].
Haemolysis assay
The bacteria were grown overnight on CSBA plates at
37 °C at 5 % CO2 and then cultured overnight in 5 ml
BHI containing 5 % FCS. 1 ml of overnight culture was
added to 5 ml BHI + FCS and subcultured until OD600nm
0.4. The bacteria were then centrifuged at 5000 x g for
10 min at room temperature and resuspended in 100 μl
PBS. To release haemolysins from the bacteria, they
were sonicated for 5 min on ice. In a round-bottomed
96-well plate (Sarstedt, NC, USA), 50 μl PBS (pH 7.4)
was added per well along with 50 μl of bacterial sonicate
or 50 μl pneumolysin (2 mg/ml, as a positive control) and
doubling dilutions made across the plate. One row of wells
was used as negative control (PBS only). 50 μl of 2 %
sheep red blood cell suspension in PBS was added per well
and incubated for 30 min at 37 °C and lysis monitored.
Statistics
To assess the significance of the results ANOVA (with
Tukey’s post hoc test) or student t test was used in
GraphPad Prism as indicated. A p value < 0.05 was con-
sidered statistically significant.
Results
Clinical pneumococcal isolates varied in their induction of
CXCL8 from epithelial cells
The CXCL8 response from Detroit 562 human pharyngeal
epithelial cells was measured following exposure to a se-
lection of clinical pneumococcal isolates of different sero-
types. CXCL8 concentrations varied according to the
pneumococcal strain, ranging from 2909 pg/ml for the
serotype 23 F strain to 8092 pg/ml for the serotype 15
strain (Fig. 1a). (For all strains the value was significantly
greater than the mean CXCL8 concentration for Detroit
cells only which was 471 pg/ml). The strain of serotype 15
induced significantly more CXCL8 than either the strains
of serotype 23 F or 7 F (assessed by ANOVA with Tukey’s
post hoc test) but there were no other significant differ-
ences in CXCL8 induction between the clinical isolates.
To determine whether serotype plays a role in level of
CXCL8 response, we compared the effects of a 6B clinical
isolate (strain 106.66) with its capsule deletion mutant
(106.66Janus) and capsule switch mutants with the same
genetic background expressing capsules of eight different
serotypes (Fig. 1b) i.e. with the genetic background of
strain 106.66 but expressing the capsules of the clinical
strains in Fig. 1a (Table 1). CXCL8 response varied be-
tween the lowest value of 2384 pg/ml observed for sero-
type 18C and the highest 4209 pg/ml for the 6B parent
strain but no differences were statistically significant by
ANOVA.
Liposomes reduced CXCL8 from epithelial cells exposed
to different clinical pneumococcal isolates
As the most important virulence factor in inducing a
CXCL8 response in the epithelial cells is thought to be
pneumolysin, we tested the effectiveness of liposomes
which absorb cholesterol-dependent toxins, such as
pneumolysin, in reducing the CXCL8 response to differ-
ent clinical pneumococcal isolates. We found that these
liposomes were effective for all the pneumococcal iso-
lates tested (Fig. 2). 1 mg of liposomes reduced the con-
centration of CXCL8 to a mean value of 27.7 % of that
in the absence of liposomes. 100 μg reduced CXCL8
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levels to a mean of 61.8 % of those in the absence of li-
posomes. (i.e. 1 mg of liposomes reduced CXCL8 levels
by a mean of 72.3 % and 100 ug by 38.2 %).
Lytic antibiotic is required to induce CXCL8 response to
serotype 3 strain P21, which was reduced by liposomes
Unlike the other wild type clinical isolates in this study,
strain P21, serotype 3, has been passaged in an animal
model and has an extremely thick capsule. Using the
same protocol as used for the strains in Figs. 1 and 2 we
found no induction of CXCL8 release by strain P21
(Fig. 3a). However, treatment with the lytic antibiotic
ceftriaxone enabled strain P21 to induce a CXCL8 re-
sponse which was reduced by the presence of liposomes
(Fig. 3b).
Reduction of CXCL8 response by liposomes depended on
haemolytic activity of serotype 1 pneumococcal strains
Haemolytic activity was determined for four serotype 1
clinical isolates (Additional file 1: Figure S1) and used to
assign them as haemolytic, poorly haemolytic or non-
haemolytic. The non-haemolytic strains did not trigger
CXCL8 levels above the baseline secretion by epithelial
cells suggesting that, without active pneumolysin, these
strains were not releasing any other significant CXCL8-
inducing factors. For the haemolytic and poorly haemo-
lytic strains, liposomes significantly reduced CXCL8
concentration (p < 0.05 for 1 mg liposomes) (Fig. 4).
Since the non-haemolytic strains did not induce CXCL8
production in Detroit 562 cells, liposome treatment had
no observable effect.
Liposomes acted on pneumolysin and another virulence
factor
To determine whether the effect of the liposomal formu-
lation was entirely due to their ability to neutralize
pneumolysin, we analysed their effect on CXCL8 levels
from Detroit cells exposed to the pneumococcal labora-
tory strain D39 (serotype 2) and its mutants in which
pneumolysin or capsule or both had been deleted.
Figure 5 shows that, as expected, liposomes reduced
(a) 
(b) 
Fig. 1 Effect of pneumococcal strains of different serotypes on CXCL8
induction in human nasopharyngeal epithelial cells. Detroit 562
nasopharyngeal epithelial cells were assessed for CXCL8 release after
exposure to wildtype (a) or capsule switch mutant (b) pneumococcal
strains. a Strain 207.31 induced more CXCL8 than either strain 103.57
or strain 208.41 but there were no other significant differences in
CXCL8 induction between the clinical isolates. b No significant
differences in CXCL8 induction were detected between any of the
strains of different serotypes but the same genetic background. All
experiments were performed in triplicate. Serotypes are indicated in
brackets, NT refers to the nontypeable capsule deletion mutant.
Negative control refers to Detroit cells in the absence of bacteria.
* indicates significant difference by ANOVA with Tukey’s post hoc test.
Error bars indicate standard deviation
μ
Fig. 2 Liposomes (1 mg or 100 μg) reduced CXCL8 concentration
from human nasopharyngeal epithelial cells induced by different
pneumococcal strains. Values shown are means of three
independent experiments and are the values with 1 mg or 100 μg
of liposomes expressed as percentages of the CXCL8 concentrations
obtained in the absence of liposomes in the presence of wild type
clinical isolates. Liposomes reduced the CXCL8 response to all
pneumococcal strains tested. Numbers in brackets indicate
serotypes. Error bars indicate standard deviation
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CXCL8 levels following exposure to D39 strain, which
possesses both capsule and pneumolysin. However, the
liposomes also had a significant effect in the mutant in
which the pneumolysin gene had been deleted (D39Δply)
indicating efficacy against a proinflammatory bacterial
factor other than pneumolysin. Consistent with this, 1 mg
liposomes also reduced CXCL8 concentration induced by
the capsule-deficient mutant (D39Δcps) (which has pneu-
molysin) and the mutant lacking both pneumolysin and
capsule (D39ΔplyΔcps).
Discussion
An excessive inflammatory response can cause damage
to the host during pneumococcal diseases which may be
exacerbated by treatment with lytic antibiotics as they
cause release of inflammatory factors. The cholesterol-
dependent toxin pneumolysin plays an important role in
induction of inflammation but the presence of capsule
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Fig. 3 Treatment of serotype 3 strain P21 with lytic antibiotic is
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Fig. 5 CXCL8 responses of human nasopharyngeal epithelial cells to
pneumococcal strain D39 (serotype 2) and its mutants lacking
pneumolysin (D39Δply) or capsule (D39Δcps) or both (D39ΔplyΔcps)
in the absence and presence (1 mg or 100 μg) of liposomes.
Liposomes reduced CXCL8 levels following exposure to the wildtype
strain D39 strain but also reduced the CXCL8 response to its mutants
lacking pneumolysin. * indicates significant difference. Error bars
indicate standard deviation
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has also been shown to have an influence [11, 14, 15].
Here we determined whether the inflammatory response,
as measured by release of the inflammatory cytokine
CXCL8 from human nasopharyngeal epithelial cells in
vitro, was affected by the pneumococcal serotype. The
pneumococcal clinical isolates tested induced different
amounts of the inflammatory cytokine CXCL8 (Fig. 1a).
By using capsule switch mutants we have shown that
capsule serotype had no significant effect on CXCL8
levels, under the in vitro conditions used (Fig. 1b). Dele-
tion of capsule in strain D39 resulted in an increase in
release of CXCL8 from the epithelial cells but when cap-
sule was deleted in strain 106.66 no significant difference
in CXCL8 was observed, suggesting a strain-specific ef-
fect. Cytokine networks involved in pneumococcal infec-
tions are incompletely understood but IL-1β has been
shown to regulate CXCL8 release from epithelial cells in
reponse to S. pneumoniae [16] and would be an interest-
ing target for future study. Furthermore, it has also been
shown, in vivo, that pneumococcal capsule could impair
recognition by the innate immune system, in particular
the Toll-like receptor mediated pathways [17]. However,
the most evident difference was between wild types and
pneumolysin mutants indicating that pneumolysin is the
predominant CXCL8 inducer.
Liposomes designed to sequester cholesterol-dependent
toxins such as pneumolysin [8] caused a marked, and dose
dependent, decrease in CXCL8 release from the epithelial
cells for all the serotypes of clinical isolates tested (Fig. 2).
This indicates the potential of this liposome treatment to
be effective against pneumococcal diseases caused by dif-
ferent pneumococcal strains in patients.
In pneumococcal meningitis mortality and morbidity
are exacerbated by an excessive inflammatory response.
Treatment with lytic antibiotic, although effective at kill-
ing the bacteria, causes release of pneumolysin triggering
an even greater inflammatory response. In an infant rat
model of pneumococcal meningitis a serotype 3 strain
(P21) is often used to induce the disease [18] and here
we have shown that in vitro, following antibiotic lysis,
which would release the pneumolysin, liposome treat-
ment greatly reduced CXCL8 levels from the epithelial
cells (Fig. 3). This raises the possibility of a future anti-
inflammatory treatment for pneumococcal meningitis
including this liposomal formulation. Serotype 3 strains
are also associated with severe forms of pneumonia and
with septic shock [19, 20] and so the effectiveness of the
liposome treatment against this serotype, as least in
vitro, is encouraging.
In nature several different alleles of pneumolysin exist
with differing haemolytic activity [6, 21]. Serotype 1 has
particularly been noted to include non-haemolytic and
poorly-haemolytic variants. We found liposomes to be
effective at reducing the CXCL8 response to haemolytic
and poorly-haemolytic strains (Fig. 4). Non-haemolytic
strains did not trigger CXCL8 levels above the baseline se-
cretion by epithelial cells so liposomes did not reduce the
level further. Overall, the results indicate that liposomes
may be useful in counteracting the inflammatory effect of
a wide range of clinical pneumococcal strains of different
haemolytic activity as well as different serotypes.
Using pneumolysin and capsule mutants of strain D39
(Fig. 5), we showed for the first time that the liposomes
act not only on pneumolysin, but also significantly re-
duce the CXCL8 response to another factor which re-
mains to be identified.
Conclusions
We found that clinical pneumococcal isolates varied in
their capacity to induce CXCL8 production by respira-
tory epithelial cells. Capsule type had little effect on this
variation compared with pneumolysin which had the
predominant effect. Liposomes designed to sequester
pneumolysin were extremely effective in vitro in redu-
cing CXCL8 levels from epithelial cells exposed to a
range of clinical pneumococcal isolates. Liposomes also
reduced CXCL8 release induced by mutant pneumococci
lacking pneumolysin indicating that they also act on an-
other factor.
Additional file
Additional file 1: Figure S1. Results of haemolysis assay for four different
serotype 1 clinical isolates. Figure S2. Showing no effect on viability of
pneumococcal strain 106.66 by 1mg of liposomes after 30, 120 and 240
minutes of culture. (DOC 439 kb)
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